Clinical Trial Update: Autologous T Cell Vaccine (TCV) for Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial of an autologous T cell vaccine (TCV) for relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Autologous T Cell Vaccine (TCV)

Snippet

Sponsor: Opexa Therapeutics, Inc. | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED